- Home
- TXMD vs INTS Comparison
TXMD vs INTS Comparison
Compare TXMD & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- INTS
- Stock Information
- Founded
- TXMD 2008
- INTS 2012
- Country
- TXMD United States
- INTS United States
- Employees
- TXMD N/A
- INTS N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- TXMD Health Care
- INTS Health Care
- Exchange
- TXMD Nasdaq
- INTS Nasdaq
- Market Cap
- TXMD 12.3M
- INTS 12.2M
- IPO Year
- TXMD N/A
- INTS 2023
- Fundamental
- Price
- TXMD $1.23
- INTS $0.25
- Analyst Decision
- TXMD
- INTS Strong Buy
- Analyst Count
- TXMD 0
- INTS 4
- Target Price
- TXMD N/A
- INTS $4.50
- AVG Volume (30 Days)
- TXMD 506.6K
- INTS 5.8M
- Earning Date
- TXMD 11-12-2025
- INTS 11-12-2025
- Dividend Yield
- TXMD N/A
- INTS N/A
- EPS Growth
- TXMD N/A
- INTS N/A
- EPS
- TXMD N/A
- INTS N/A
- Revenue
- TXMD $2,559,000.00
- INTS N/A
- Revenue This Year
- TXMD $427.09
- INTS N/A
- Revenue Next Year
- TXMD N/A
- INTS N/A
- P/E Ratio
- TXMD N/A
- INTS N/A
- Revenue Growth
- TXMD 156.93
- INTS N/A
- 52 Week Low
- TXMD $0.70
- INTS $0.19
- 52 Week High
- TXMD $2.44
- INTS $3.40
- Technical
- Relative Strength Index (RSI)
- TXMD 59.44
- INTS 45.63
- Support Level
- TXMD $1.20
- INTS $0.23
- Resistance Level
- TXMD $1.37
- INTS $0.26
- Average True Range (ATR)
- TXMD 0.12
- INTS 0.03
- MACD
- TXMD 0.02
- INTS -0.00
- Stochastic Oscillator
- TXMD 29.85
- INTS 19.88
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.